BioCentury | Apr 4, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: March 2018

New Therapeutic Targets and Biomarkers: March 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during March 2018. Therapeutic targets are defined as any protein, gene or other...
BioCentury | Apr 3, 2018
Translation in Brief

Strong-arming drug delivery

...environmental genetics and pathophysiology at Harvard T. H. Chan School of Public Health, showed that arrestin domain containing 1 (ARRDC1)...
...macromolecules .” Nature Communications. (2018) Elizabeth S. Eaton, Staff Writer Harvard T. H. Chan School of Public Health Arrestin domain containing 1 (ARRDC1) CRISPR-associated...
BioCentury | Mar 28, 2018
Distillery Techniques

Drug delivery

...Next steps include testing microvesicles containing the ARRDC1-p53 fusion protein in models of cancer. DESCRIPTION: Arrestin domain containing 1 (ARRDC1)-containing...
...of Public Health, Boston, Mass. email: qlu@hsph.harvard.edu Elizabeth S. Eaton Harvard T. H. Chan School of Public Health Arrestin domain containing 1 (ARRDC1) p53 Tat...
BioCentury | Sep 15, 2016
Distillery Therapeutics

Therapeutics: MLX interacting protein (MLXIP); thioredoxin interacting protein (TXNIP); arrestin domain containing 4 (ARRDC4)

Endocrine/metabolic disease INDICATION: Obesity Cell culture and mouse studies suggest inhibiting the MLXIP / TXNIP / ARRDC4 pathway could help treat obesity. In cultured human skeletal myotubes, siRNA targeting MLXIP or a MLXIP inhibitor tool...
BioCentury | Oct 27, 2011
Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Obesity Arrestin domain containing 3 (ARRDC3) Mouse and human sample studies suggest decreasing levels of ARRDC3 could help treat male obesity. In human adipose...
Items per page:
1 - 5 of 5